IcoSema is a once-weekly injection combining basal insulin icodec with semaglutide. It received EU marketing authorization as Kyinsu on November 24, 2025, for adults with type 2 diabetes inadequately controlled on basal insulin or GLP-1 receptor agonists, alongside diet, exercise and oral diabetes medicines [5].
In October 2026, EMA’s medicines committee recommended extending that indication. The recommendation is a separate step from a change to the marketing authorization [6]. The CagriSema diabetes trials studied a different combination. CagriSema contains cagrilintide and semaglutide, with no insulin in the combination itself.
Three trials, three comparators
The first three COMBINE trials lasted 52 weeks and used different active comparators. The table reports estimated differences from those trials.
| Trial | Compared with | HbA1c difference | Weight |
|---|---|---|---|
| COMBINE 1, n=1,291 | weekly insulin icodec | −0.66 points | −5.59 kg difference |
| COMBINE 2, n=683 | semaglutide 1.0 mg | −0.44 points | +0.84 kg vs −3.70 kg |
| COMBINE 3, n=679 | basal-bolus insulin | −0.06 points | −6.72 kg difference |
In COMBINE 1, HbA1c fell 1.55 points on IcoSema and 0.89 points on weekly insulin icodec. The estimated difference was −0.66 points [2]. The meta-analysis reports a weight difference of −5.59 kg from this trial [1].
COMBINE 2 enrolled adults already on a GLP-1. The estimated HbA1c difference was −0.44 points versus semaglutide 1.0 mg [3]. Weight went the other way: up 0.84 kg on IcoSema, down 3.70 kg on semaglutide.
COMBINE 3 compared weekly IcoSema with daily basal-bolus therapy. The HbA1c difference was −0.06 points (95% CI −0.22 to 0.09), meeting the trial’s noninferiority criterion [4]. Weight favored IcoSema by 6.72 kg.
Why the pooled number reads 98%
A 2026 meta-analysis pooled COMBINE 1 and COMBINE 3, 1,970 people [1]. It left out COMBINE 2 for asking a different question.
The pooled HbA1c difference was −0.37 percentage points (95% CI −0.95 to 0.21). The I² was 98% [1].
The studies differed in their estimated effects. Their different insulin comparators may help explain the inconsistency. With just two trials, the individual estimates are more informative for a specific comparison [1].
What moved beyond glucose
Compared with insulin-based regimens, pooled mean differences favored IcoSema for weight (−6.10 kg) and systolic blood pressure (−2.45 mmHg). LDL cholesterol and triglycerides each had an estimated treatment ratio of 0.94 [1].
Hypoglycemia fell sharply against insulin. Severe or clinically significant episodes ran 0.14 per person-year of exposure versus 0.63 on icodec [2]. Against basal-bolus therapy they ran 0.21 versus 2.23 [4]. Compared with semaglutide alone, the trial detected no statistically significant difference [3].
Our guide to low blood sugar with insulin and GLP-1 medicines explains why what a patient takes alongside a GLP-1 affects risk. IcoSema contains insulin.
How the regimens differ
IcoSema was given weekly in all three trials. In COMBINE 3, the comparator used daily basal insulin plus mealtime insulin [4]. Those findings apply to the regimens and adults studied and do not predict how a medication change would affect an individual patient.